Bio-Rad Laboratories (BIO) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Bio-Rad Laboratories (BIO) right now is Sartorius stake and activist pressure: Bio-Rad's roughly 28% holding in Sartorius is worth close to its entire market value, so movements in that German stock swing Bio-Rad's book value and sentiment heavily. Revenue (TTM) is ~$2.58B. If that keeps playing out, the setup is favourable; the risk to it is the 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. No one can predict where BIO trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Bio-Rad Laboratories (BIO) higher?
1. Sartorius stake and activist pressure
Bio-Rad's roughly 28% holding in Sartorius is worth close to its entire market value, so movements in that German stock swing Bio-Rad's book value and sentiment heavily. Elliott's May 2026 stake and its stated push to improve the share price and unlock the Sartorius value make capital allocation (monetization, buybacks, or restructuring) a central catalyst. How management responds is arguably the biggest single driver of the equity.
2. Digital PCR and Life Science recovery
Droplet digital PCR remains a differentiated franchise, with instrument revenue up about 24% year over year and the new QX700 platform rolling out ahead of plan on assay enablement. A rebound in biopharma and academic instrument spending, which has been depressed across the tools sector, would lift the higher-margin Life Science segment. Consumables pull-through on a growing installed base supports recurring revenue.
3. Diagnostics stability and margin recovery
Clinical Diagnostics provides a recurring, less cyclical base through blood typing, quality controls, and diabetes monitoring used in routine lab workflows. Management is targeting operating-margin improvement over time through cost discipline and mix, though the 2026 outlook was reset lower. Stabilizing the diagnostics franchise and rebuilding margin is key to the operating-company narrative that activists want the market to credit.
What could weigh on BIO?
The 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. A Middle East conflict reduced first-quarter revenue and remains a headwind for the blood-typing diagnostics business, which drew a meaningful share of the segment from that region. Because the Sartorius stake dwarfs the operating business in value, Bio-Rad's stock and reported results are highly sensitive to that single holding, and reported GAAP earnings can swing to losses on non-cash marks. Instrument demand across life-science tools has been weak, and any activist campaign carries execution and timing uncertainty. Dual-class shares concentrate voting control with the founding family, which can limit outside influence over the pace of change.
Where BIO trades today
A forecast starts from where the stock actually is. These are BIO's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for BIO as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a BIO forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the BIO guide and whether BIO is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the BIO outlook
The bottom line: what is driving Bio-Rad Laboratories (BIO) is Sartorius stake and activist pressure, with revenue (ttm) at ~$2.58B. If that keeps playing out the setup is favourable; the risk is the 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. No one can predict the price, so treat any BIO forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
More on BIO
- BIO stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- Is BIO a buy? (the case for, the risks, and a framework to decide)
- Does BIO pay a dividend?
Build a basket around BIO with Walnut
Use Bio-Rad Laboratories as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Bio-Rad Laboratories (BIO)?
+
No one can reliably predict where BIO will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Bio-Rad Laboratories higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive BIO higher?
+
The main growth drivers are Sartorius stake and activist pressure; Digital PCR and Life Science recovery; Diagnostics stability and margin recovery. Whether they play out is the real question, not a guaranteed path.
What are the risks to BIO?
+
The 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. A Middle East conflict reduced first-quarter revenue and remains a headwind for the blood-typing diagnostics business, which drew a meaningful share of the segment from that region. Because the Sartorius stake dwarfs the operating business in value, Bio-Rad's stock and reported results are highly sensitive to that single holding, and reported GAAP earnings can swing to losses on non-cash marks. Instrument demand across life-science tools has been weak, and any activist campaign carries execution and timing uncertainty. Dual-class shares concentrate voting control with the founding family, which can limit outside influence over the pace of change.
Will BIO stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Bio-Rad Laboratories's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is BIO a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the BIO "is it a buy?" page for a framework. Walnut is not an investment adviser.
How did Bio-Rad perform in Q1 2026?
+
Bio-Rad reported first-quarter 2026 revenue of about $592 million and non-GAAP EPS of roughly $1.89, slightly ahead of some estimates on earnings. Management cut its full-year outlook, citing a Middle East conflict that hurt its blood-typing diagnostics business.
Why was Bio-Rad's 2026 guidance cut?
+
Management lowered currency-neutral revenue guidance to roughly a 3% decline to about 0.5% growth and trimmed operating margin toward 10% to 12%, driven largely by a Middle East conflict that reduced diagnostics revenue plus soft life-science instrument demand.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.